Symbols

ATRC

AtriCure·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Consensus Rating "Strong Buy"

Bearish Engulfing

Ample Liquidity

High Gross Profit Margin

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ATRC

Atricure, Inc.

A leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management

Industry

Healthcare Equipment and Supplies

Established Date

10/31/2000

Listing Date

08/05/2005

Exchange

NASDAQ Stock Exchange

Full-time Employees

1,350

Fiscal Year Ends

12-31

Website

www.atricure.com

Security Type

Common stock

Office address

7555 Innovation Way , Mason , OH 45040

Business

Introduction

AtriCure, Inc., was incorporated in Delaware on October 31, 2000. The company is a leading innovator in surgical treatments and therapies for atrial fibrillation, left atrial appendage management and postoperative pain management. The company's cardiac ablation and left atrial appendage management products are used by physicians in open heart and minimally invasive surgery. The company's pain management solutions are used by doctors to freeze nerves during heart, chest or amputation surgery. The company's cryoICE frozen balls and cryoXT probes for pain management provide temporary relief of postoperative pain, allowing the patient's body to heal after surgery, while nerve regeneration and sensory recovery. The company sells to medical centers through its direct sales teams in the United States, Germany, France, the United Kingdom, the Benelux region, Australia and Canada. The company also sells its products through distributors, who in turn sell their products to medical centers in other international markets.

Company Financials

EPS

ATRC has released its 2025 Q4 earnings. EPS was reported at 0.06, versus the expected -0.1, beating expectations. The chart below visualizes how ATRC has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ATRC has released its 2025 Q4 earnings report, with revenue of 140.50M, reflecting a YoY change of 13.05%, and net profit of 1.76M, showing a YoY change of 111.28%. The Sankey diagram below clearly presents ATRC's revenue sources and cost distribution.